Lantern Pharma Inc (LTRN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.81M
Last updated: Nov 17, 2026 at 4:10 PM ET
Lantern Pharma Inc (LTRN) Statistics
Lantern Pharma (LTRN) has a market cap of $5.81M. Its share count is up 24.67% from a year earlier. It holds $7.61M more cash than debt, 130.96% of its market cap.
Total Valuation
| Market Cap | $5.81M |
|---|---|
| Latest price (Nov 17, 2026) | $0.36 |
Key Dates
The next earnings report is expected on Nov 17, 2026, covering the quarter ending Sep 30, 2026.
| Next Earnings Date | Nov 17, 2026 (expected) |
|---|---|
| Last Earnings Date | Aug 14, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 89.20% over 52 weeks and trades 61.29% below its 50-day average.
| Beta (1Y) | 3.04 |
|---|---|
| 52-Week Change | -89.20% |
| 1-Month Change | -43.08% |
| 3-Month Change | -85.34% |
| 6-Month Change | -88.19% |
| 5-Year Change | -93.53% |
| Total Return (1Y) | -89.20% |
| Total Return (3Y CAGR) | -55.08% |
| Total Return (5Y CAGR) | -46.82% |
| Max Drawdown (1Y) | -91.25% |
| Max Drawdown (3Y) | -96.57% |
| Sharpe Ratio (1Y) | -1.92 |
| Correlation with SPY (1Y) | 0.37 |
| 50-Day Average | $0.93 |
| 200-Day Average | $2.29 |
| 52-Week Range | $0.38 to $4.34 |
| RSI (14 Days) | 23.9 |
| Average Volume (20 Days) | 182.64K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.49x current liabilities, and total debt is 0.01x shareholder equity.
| Current Ratio | 1.49x |
|---|---|
| Quick Ratio | 1.49x |
| Debt / Equity | 0.01x |
Returns and Efficiency
Return on invested capital is -778.39% over the last 12 months, against a 5-year average of -71.79%.
| Return on Equity (ROE) | -977.05% |
|---|---|
| Return on Assets (ROA) | -161.64% |
| Return on Invested Capital (ROIC) | -778.39% |
| ROE (5Y Average) | -88.36% |
| ROA (5Y Average) | -62.78% |
| ROIC (5Y Average) | -71.79% |
Scores
LTRN has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue of $0 over the last 12 months is down 100.00% from the 12 months before.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | $4.10K |
| Operating Income | -$16.49M |
| Pretax Income | -$13.79M |
| Net Income | -$13.78M |
| Reported EPS (TTM) | -$1.33 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 16.55% of the $8.52M in total assets.
| Cash and Equivalents | $7.62M |
|---|---|
| Total Debt | $7.11K |
| Net Cash | $7.61M |
| Net Cash Per Share | $0.56 |
| Working Capital | $2.76M |
| Shareholder Equity | $1.41M |
| Book Value Per Share | $0.10 |
| Total Assets | $8.52M |
| Total Liabilities | $7.11M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$12.85M |
|---|---|
| FCF Per Share | -$0.86 |
| Depreciation and Amortization | $40.68K |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -60.21% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -60.21% |
Dividends and Yields
LTRN does not pay a dividend.
| Buyback Yield | -87.05% |
|---|---|
| Shareholder Yield | -87.05% |
Peer Position
Against 4 similar companies, LTRN has the 4th highest ROIC.
ROICPeer median -202.00%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -99.32%
| ROIC | -778.39% vs -202.00% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs -99.32% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About LTRN
What is LTRN's market cap?
Lantern Pharma has a market cap of $5.81M.
How many shares of LTRN are outstanding?
Lantern Pharma has 13.51M shares outstanding. The count is up 24.67% from a year earlier.
Does LTRN pay a dividend?
No. Lantern Pharma does not pay a dividend.
How much debt does LTRN have?
Lantern Pharma has $7.11K of total debt and $7.62M of cash and equivalents, a net cash position of $7.61M.
LTRN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors